We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

Objective: To quantitate the separate impact of obesity and hyperlycemia on the incretin effect (i.e., the gain in β-cell function after oral glucose versus intravenous glucose). Research Design ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

The lower sales guidance was a result of sluggish growth in the market for incretin, which increases insulin levels. “Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

The lower sales guidance was a result of sluggish growth in the market for incretin, which increases insulin levels. "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect ...